Hillstream BioPharma Announces Acceptance of Abstract at AACR 2023 Annual Meeting Highlighting HSB-510 as Novel Bi-functional Inhibitor for Solid Tumors & Leukemias

February 8, 2023

https://www.globenewswire.com/news-release/2023/02/08/2603811/0/en/Hillstream-BioPharma-Announces-Acceptance-of-Abstract-at-AACR-2023-Annual-Meeting-Highlighting-HSB-510-as-Novel-Bi-functional-Inhibitor-for-Solid-Tumors-Leukemias.html

Preclinical Update on HSB-510 and navitoclax, a Novel Quatramer™-based, First-in-Class Dual Inhibitor of PI3-Kδ/HDAC6 in combination with navitoclax (BCL-XL/BCL-2 inhibitor)

Read more at globenewswire.com

Related news for (HILS)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.